MTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: A critical review

Gynecologic Oncology

Volumn 133, Issue 2, 2014, Pages 375-381

  Husseinzadeh, Nader ^a   Husseinzadeh, Holleh D ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cervical; Endometrial; Gynecologic cancer; mTOR; Ovarian cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYTOSTATIC AGENT; CYTOTOXIC AGENT; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; IXABEPILONE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLANT MEDICINAL PRODUCT; PLATINUM; PROTEIN KINASE B; PROTEIN P53; RAPAMYCIN; RIDAFOROLIMUS; TAMOXIFEN; TEMSIROLIMUS; TOPOTECAN; VASCULOTROPIN INHIBITOR;

ADJUVANT CHEMOTHERAPY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CELL PROLIFERATION; CELL SIGNALING ASSAY; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FATIGUE; GENE MUTATION; GENE OVEREXPRESSION; GYNECOLOGIC CANCER; HUMAN; MEDLINE; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; OVARY CANCER; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; STOMATITIS; SYSTEMATIC REVIEW; TUMOR GROWTH; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

CERVICAL; ENDOMETRIAL; GYNECOLOGIC CANCER; MTOR; OVARIAN CANCER;

ANTINEOPLASTIC AGENTS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; OVARIAN NEOPLASMS; SIROLIMUS; TOR SERINE-THREONINE KINASES; UTERINE CERVICAL NEOPLASMS;

EID: 84899629953     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.02.017     Document Type: Review

References (73)

1. D.C. Fingar, C.J. Richardson, A.R. Tee, L. Cheatham, C. Tsou, and J. Blenis mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E Mol Cell Biol 24 2004 200 216
2. D.A. Guertin, and D.M. Sebatin Defining the role of mTOR in cancer Cancer Cell 12 2007 9 22
3. C.C. Hudson, M. Liu, G.C. Chiang, D.M. Otterness, D.C. Loomis, and F. Kaper et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin Mol Cell Biol 22 2002 7004 7014
4. P.H. Maxwell, C.W. Pugh, and P.J. Radcliffe Activation of the HIF pathway in cancer Curr Opin Genet Dev 11 2001 293 299
5. S. Wullschleger, R. Loewith, and M.N. Hall TOR signaling in growth and metabolism Cell 124 2006 471 484
6. C.C. Thoreen, L. Chantranupong, H.R. Keys, T. Wang, N.S. Gray, and D.M. Sabatini A unifying model for mTORC1-mediated regulation of mRNA translation Nature 485 7396 2012 109 113
7. T. Peng, T.R. Golub, and D.M. Sabatini The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation Mol Cell Biol 22 2002 5575 5584
8. A.R. Tee, and J. Blenis mTor, translational control and human disease Semin Cell Dev Biol 16 2005 29 37
9. D.E. Martin, and M.N. Hall The expanding TOR signaling network Curr Opin Cell Biol 17 2005 158 166
10. N. Hay, and N. Soneneberg Upstream and downstream of mTOR Genes Dev 18 2004 1926 1945
11. E. Jacinto, and M.N. Hall TOR signalling in bugs, brain and brawn Nat Rev Mol Cell Biol 4 2003 117 126
12. M. Laplante, and D.M. Sabatini mTOR signaling in growth control and disease Cell 149 2012 274 293
13. H. Pópulo, J.M. Lopes, and P. Soares The mTOR signaling pathway in human cancer Int J Mol Sci 13 2012 1886 1918
14. S. Sengupta, T.R. Peterson, and D.M. Sabatini Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress Mol Cell 40 2010 310 322
15. J.B. Brugarolas, F. Vasquez, A. Reddy, W.R. Sellers, and W.G. Kaelin TSC2 regulates VEGF through mTOR-dependent and independent pathway Cancer Cell 4 2003 147 158
16. C. He, and D.J. Klionsky Regulation mechanisms and signaling pathways of autophagy Annu Rev Genet 43 2009 67 93
17. S. Huang, and P.J. Houghton Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic Curr Opin Invest Drugs 3 2002 295 304
18. S. Faivre, G. Kroemer, and E. Raymond Current development of mTOR inhibitors as anticancer agents Nat Rev Drug Discov 8 2006 671 688
19. L.F. Costa, M. Balcells, E.R. Edelman, L.M. Nadler, and A.A. Cardoso Pro-angiogenic stimulation of bone marrow endothelium engages mTOR, and is inhibited by simultaneous blockade of mTOR and NF-B Blood 107 2006 285 292
20. F. Meric-Bernstam, and A.M. Gonzalez-Angulo Targeting the mTOR signaling network for cancer therapy J Clin Oncol 13 2008 2278 2287
21. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, and S. Szabo et al. High frequency of mutations of the PIK3CA gene in human cancers Science 304 2004 554
22. F. Janku, J.J. Wheler, S.N. Westin, S.L. Moulder, A. Naing, and A.M. Tsimberidou et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations J Clin Oncol 30 2012 777 782
23. S. Faivre, G. Kroemer, and E. Raymond Current development of mTOR inhibitors as anticancer agents Nat Rev Drug Discov 5 2006 671 688
24. R.D. Rao, J.C. Buckner, and J.N. Sarkaris Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents Curr Cancer Drug Targets 4 2004 621 635
25. F.X. Bosch, A. Lorincz, N. Muñoz, C.J. Meijer, and K.V. Shah The causal relation between human papillomavirus and cervical cancer J Clin Pathol 55 2002 244 265
26. X.Y. Zhang, H.Y. Zhang, P.N. Zhang, X. Lu, and H. Sun Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer Eur J Obstet Gynecol Reprod Biol 139 2008 237 244
27. L.S. Faried, A. Faried, T. Kanuma, T. Santo, T. Nakazato, and T. Tamura et al. Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with neoadjuvant chemotherapy Oncol Rep 16 2006 57 63
28. L.S. Faried, A. Faried, T. Kanuma, H. Aoki, T. Sano, and T. Nakazato et al. Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix. A potential biomarker and molecular target therapy Mol Carcinog 47 2008 446 457
29. W. Feng, X. Duan, J. Liu, J. Xiao, and R.E. Brown Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions Int J Exp Pathol 3 2009 249 260
30. M.-N. Kim, Y.-J. Kim, C.O. Sung, C.H. Choi, J.-W. Lee, and Kim B-g et al. High expression of mTOR is associated with radiation resistance in cervical cancer J Gynecol Oncol 21 2010 181 185
31. A.V. Tinker, S. Ellard, S. Welch, F. Moens, G. Allo, and M.S. Tsao et al. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199) Gynecol Oncol 130 2013 269 274
32. J. Wu, C. Chen, and K.M. Zhao Phosphatidylinositol 3-kinase signaling as a therapeutic target for cervical cancer Curr Cancer Drug Targets 13 2013 143 156
33. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
34. J.L. Hecht, and G.L. Mutter Molecular and pathologic aspects of endometrial carcinogenesis J Clin Oncol 24 2006 4783 4791
35. N. Bansal, V. Yendluri, and R.M. Wenham The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies Cancer Control 16 2009 8 13
36. T. Fujimoto Endometrioid uterine cancer: histopathological risk factors of local and distant recurrence Gynecol Oncol 112 2009 342 347
37. C.A. Hamilton Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers Br J Cancer 94 2006 642 646
38. C. Zhou, V.L. Bae-Jump, Y.E. Whang, P.A. Gehrig, and J.F. Boggess The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels Gynecol Oncol 101 2006 305 310
39. G.L. Mutter, M.C. Lin, J.T. Fitzgerald, J.B. Kum, J.P. Baak, and J.A. Lees et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers J Natl Cancer Inst 92 2000 924 930
40. B.M. Slomovitz, W. Wu, R.R. Broaddus, P.T. Soliman, J. Wolf, and C.C. Sun mTOR inhibition is a rational target for the treatment of endometrial cancer Proc Am Soc Clin Oncol 22 2004 5076
41. B.M. Slomovitz, K.H. Lu, T. Johnston, R.L. Coleman, M. Munsell, and L.M. Ramondetta et al. A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC) J Clin Oncol 155 s 5502 2008
42. B.M. Slomovitz, K.H. Lu, T. Johnston, R.L. Coleman, M. Munsell, and R.R. Broaddus et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma Cancer 23 2010 5415 5419
43. N. Colombo, S. McMeekin, P. Schwartz, J. Kostka, C. Sessa, and P. Gehrig et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer J Clin Oncol (Meet Abstr) 25 2007 5516
44. H. Mackay, S. Welch, M.S. Tsao, J.J. Biagi, L. Elit, and P. Ghatge et al. Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced endometrial cancer; NCIC CTG IND 192 J Clin Oncol 29 s 5013 2011
45. A.M. Oza, L. Elit, M.-S. Tsao, S. Kamel-Reid, J. Biagi, and D.M. Provencher et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group J Clin Oncol 24 2011 3278 3285
46. V.L. Bae-Jump, C. Zhou, J.F. Boggess, and P.A. Gehring The effect of rapamycin on progesterone receptor and estrogen receptor expression in endometrial cancer cells Gynecol Oncol 108 2008 168 (Abstract)
47. S.M. Temkin, and G. Gin Fleming Current treatment of metastatic endometrial cancer Cancer Control 1 2009 38 45
48. G.F. Fleming, V.L. Filliaci, P. Hanjani, J.J. Burks, S.A. Davidson, and K.K. Leslie et al. Hormone therapy plus temsirolimus for endometrial cancer (EC): Gynecologic Oncology Group trial #248 J Clin Oncol 29 15 s 2011 335 s [ASCO#5014]
49. M.H. Einstein, R.M. Wenham, R. Morgan, M.C. Cristea, E.L. Stevel, and A.M. Oza et al. Phase II trial of temsirolimus and bevacizumab for initial recurrence of endometrial cancer J Clin Oncol 30s 2012 [ASCO# 5025]
50. E.A. Alvarez, W.E. Brady, J.L. Walker, J. Rotmensch, X.C. Zhou, and J.E. Kendrick et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 129 2013 22 27
51. A. Shafer, C. zhou, P.A. Gehring, J.F. Boggess, and V. Bae-jump Rapamycin potentiates the effect of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis Int J Cancer 126 2010 1144 1154
52. http://seer.cancer.gov/statfacts/html/ovary.
53. J.D. Seidman, P. Zhao, and A. Yemelyanova Primary peritoneal high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm Gynecol Oncol 3 2011 470 473
54. N. Howlader, A.M. Noone, M. Krapcho, N. Neyman, R. Aminou, and S.F. Altekruse et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) 2012 National Cancer Institute Bethesda, MD [ http://seer.cancer. gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site]
55. J.F. Gera, I.K. Mllinghoff, Y. Shi, M.B. Rettig, C. Tran, and J.H. Hsu et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression Biol Chem 279 2004 2737 2746
56. D.A. Altomare, H.Q. Wang, K.L. Skele, A. De Rienzo, A.J. Klein-Szanto, and A.K. Godwin et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth Oncogene 34 2004 5853 5857
57. X.B. Trinh, P.A. vanDam, L.Y. Dirix, P.B. Vermeulen, and W.A. Tjalma The rationale for mTOR inhibition in epithelial ovarian cancer Expert Opin Invest Drugs 18 2009 1885 1891
58. M. Mazzoletti Broggini M.PI3K/AKT/mTOR inhibitors in ovarian cancer Curr Med Chem 36 2010 4433 4447
59. G.T. McDonald, R. Sullivan, G.C. Pare, and C.H. Graham Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression Exp Cell Res 19 2010 3197 3206
60. K. Behbakht, M.W. Sill, K.M. Darcy, S.C. Rubin, R.S. Mannel, and S. Waggoner et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study Gynecol Oncol 1 2011 19 26
61. A. Leary, E. Auclin, P. Pautier, and Lhommé The PI3K/Akt/mTOR pathway in ovarian 6Q890 cancer; biological rationale and therapeutic opportunities. Ovarian cancer - a clinical 681 and translational update 2013 InTech; chapter 13 1030 1039 10.5772/54170
62. S. Huang, L.N. Liu, H. Hosoi, M.B. Dilling, T. Shikata, and P.J. Houghton P53/p21CIP1 cooperate in enforcing rapamycin-induced G1 arrest and determine the cellular response to rapamycin Cancer Res 61 2001 3373 3381
63. I. Beuvink, A. Boulay, S. Fumagalli, F. Zilbermann, S. Ruetz, and T. O'Reilly et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation Cell 120 2005 747 759
64. S.M. Temkin, S.D. Yamada, and G.F. Fleming A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies Gynecol Oncol 117 2010 473 476
65. C. Kollmannsberger, H. Hirte, L.L. Siu, J. Mazurka, K. Chi, and L. Elit et al. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179) Ann Oncol 23 2012 238 244
66. F. Di Nicolantonio, S. Arena, J. Tabernero, S. Grosso, F. Molinari, and T. Macarulla et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus J Clin Invest 120 2010 2858 2866
67. E. Raymond, J. Alexandre, S. Faivre, K. Vera, E. Materman, and J. Boni et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer J Clin Oncol 22 2004 2236 2247
68. K. Sankhala, A. Mita, K. Kelly, D. Mahalingam, F. Giles, and M. Mita The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents Target Oncol 4 2009 135 142
69. I. Duran, L.L. Siu, A.M. Oza, T.B. Chung, J. Sturgeon, and C.A. Townsley et al. Characterization of the lung toxicity of the cell cycle inhibitor temsirolimus Eur J Cancer 42 2006 1875 1880
70. P.T. Pham, P.C. Pham, G.M. Danovitch, D.J. Ross, H.A. Gritsch, and E.A. Kendrick et al. Sirolimus-associated pulmonary toxicity Transplantation 77 2004 1215 1220
71. W.H. Mondesire, W. Jian, H. Zhang, J. Ensor, M.C. Hung, and G.B. Mills et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy induced cytotoxicity in breast cancer cells Clin Cancer Res 10 2004 7031 7042
72. M. Campone, V. Levy, E. Bourbouloux, Berton Rigaud, D. Bootle, and C. Dutreix et al. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours Br J Cancer 100 2009 315 321
73. Diaz-Padilla, Ignacio Duran, B.A. Clark, and A.M. Oza Biologic rational and clinical activity of mTOR inhibitors in gynecologic cancer Cancer Treat Rev 38 2012 767 775